These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19038008)

  • 21. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses.
    Serke S; Schwaner I; Yordanova M; Szczepek A; Huhn D
    Cytometry; 2001 Apr; 46(2):98-104. PubMed ID: 11309819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy.
    Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R
    Ann Oncol; 2001 Aug; 12(8):1169-71. PubMed ID: 11583202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.
    Tobinai K
    Int J Hematol; 2002 Dec; 76(5):411-9. PubMed ID: 12512835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
    Duman BB; Sahin B; Ergin M; Guvenc B
    Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
    Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
    Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
    Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
    Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment.
    Miyoshi H; Arakawa F; Sato K; Kimura Y; Kiyasu J; Takeuchi M; Yoshida M; Ichikawa A; Ishibashi Y; Nakamura Y; Nakashima S; Niino D; Sugita Y; Ohshima K
    Cancer Sci; 2012 Aug; 103(8):1567-73. PubMed ID: 22500644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
    Kennedy GA; Blum R; McCormack C; Prince HM
    Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
    Clarke LE; Bayerl MG; Ehmann WC; Helm KF
    J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
    Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
    Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
    J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
    Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
    Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
    Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
    Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
    Natkunam Y; Stanton TS; Warnke RA; Horning SJ
    Clin Lymphoma; 2001 Dec; 2(3):185-7. PubMed ID: 11779297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The predictive significance of CD20 expression in B-cell lymphomas.
    Prevodnik VK; Lavrenčak J; Horvat M; Novakovič BJ
    Diagn Pathol; 2011 Apr; 6():33. PubMed ID: 21486448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
    Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
    Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.